; or (ii) national security or countermeasures or is restricted from disclosure pursuant to another provision of law. (3) Additional requirements Labeling for an in vitro clinical test used for im­mu­no­he­ma­tol­o­gy testing shall meet the following applicable requirements set forth in part 660 of the Code of Federal Regulations (or any successor regulation), related to the labeling of blood grouping reagents, reagent red blood cells, and anti-human globulin. (d) Exemptions and alternative requirements (1) In general (A) In general With respect to an in vitro clinical test that meets the criteria of subparagraph (B), the state in one place regulations under section 809.10(b) of title 21 of the Code of Federal Regulations (or any successor regulations) may be satisfied by the laboratory posting such information on its website or in multiple documents, if such documents are maintained and accessible in one place. (B) Applicable tests An in vitro clinical test meets the criteria of this subparagraph if such test is— (i) designed and manufactured by a laboratory certified by the Secretary under section 353 of the Public Health Service Act that meets the requirements for performing high-complexity testing